Application of commercial cytomegalovirus IgG avidity diagnostic kit

Clinical Laboratory
|September 5, 2014
PubMed

Insights

The Autobio CMV IgG avidity assay reliably identifies recent cytomegalovirus (CMV) infections. High avidity results, above 50% at 99 days post-seroconversion, effectively exclude recent infections within three months.

Area of Science:

  • Clinical diagnostics
  • Immunoserology
  • Viral infection detection

Background:

  • Cytomegalovirus (CMV) infection diagnosis often relies on serology when acute symptoms are absent.
  • Serological tests are crucial tools in clinical medicine for CMV detection.

Purpose of the Study:

  • To evaluate the performance of the Autobio Diagnostics Co., Ltd cytomegalovirus IgG avidity diagnostic kit for identifying recent CMV infections.
  • To compare the Autobio kit's performance against other commercial CMV IgG avidity kits using seroconversion panels.

Main Methods:

  • Evaluation of commercial CMV IgG avidity kits, including the Autobio kit.
  • Comparison of kit performance on three commercially available seroconversion panels (RP-003, RP-019, PTC901).
  • Assessment of agreement with RADIM CMV IgG avidity assay and clinical specificity using reactive and non-reactive samples.

Main Results:

  • Autobio CMV IgG avidity values >50% at 99 days post-seroconversion indicate high avidity, excluding recent infections within 3 months.
  • 100% agreement for low avidity samples and 95.0% agreement for high avidity samples when compared to the RADIM assay.
  • Clinical specificity of the Autobio CMV IgG avidity assay was determined to be 97.4% (708/727) after excluding gray zone results.

Conclusions:

  • The Autobio CMV IgG avidity assay is a reliable diagnostic tool for identifying recent cytomegalovirus infections.
  • Performance evaluation data supports the assay's utility in clinical settings for CMV diagnostics.
Abstract